Innate Pharma S.A.
IPHA
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.75
Price-0.57%
-$0.01
1Y
Price
Market Cap
$147.420m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-515.7%
EBITDA Margin-439.2%
Net Profit Margin-642.4%
Free Cash Flow MarginRevenue
$34.038m
+169.7%
1y CAGR+28.0%
3y CAGR+115.0%
5y CAGREarnings
-$80.103m
-61.9%
1y CAGR-176.1%
3y CAGR-134.6%
5y CAGREPS
-$0.98
-60.7%
1y CAGR-183.6%
3y CAGR-144.7%
5y CAGRBook Value
$5.144m
$92.937m
Assets$87.793m
Liabilities$27.029m
DebtDebt to Assets
29.1%
-0.3x
Debt to EBITDAFree Cash Flow
-$59.644m
-718.5%
1y CAGR-237.2%
3y CAGR-161.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company